Tracleer receives label extension in the US
Actelion Ltd announced that the U.S. food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for Tracleer® (bosentan) to treat patients with mildly symptomatic WHO Functional Class II (FC II) pulmonary arterial hypertension (PAH). The U.S. FDA has also approved Actelion's Risk Evaluation and Mitigation Strategy (REMS) for Tracleer®.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "Physicians in the United States of America who treat PAH patients now have access to Tracleer® as an approved therapy for patients not only in advanced, but also in the early stages of this rapidly progressing and life-threatening disease. This label extension is based on EARLY, the only randomized, double blind, placebo controlled study in this mildly symptomatic patient population. The EARLY results demonstrate that Tracleer® significantly reduces risk of clinical worsening in early-stage patients, thereby slowing down disease progression."
Tracleer® is an oral dual endothelin receptor antagonist approved for the treatment of PAH FC II, III and IV in the US and for the treatment of PAH FC II and III in the EU. The company is working with authorities on a worldwide basis to expand the label for Tracleer® to include patients with FC II PAH.
Other news from the department research and development
